Blood and lung-sample test to guide treatment for lung inflammation
Part of Infections, Injuries & trauma, Lungs & breathing clinical trials.
This Phase 1/2 study uses detailed “single-cell” testing (from lung samples) to better understand why lung inflammation happens after cancer radiation or immunotherapy. It aims to help choose the right treatment approach for people with radiation pneumonitis or immune checkpoint inhibitor pneumonitis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to under 75 years old and able to sign consent.
- You have non-small cell lung cancer with confirmed lung inflammation after radiation or immunotherapy (radiation pneumonitis or immune checkpoint inhibitor pneumonitis).
- You must NOT have taken steroid medicine (glucocorticoids) or other immune-suppressing medicines for lung inflammation before starting the study.
- You must be able to follow the study plan and be well enough for study activity (performance status 0–3).
- You must have no reasons you cannot safely do an alveolar lavage (a lung fluid wash procedure).
- You should not have recent serious infection or need ongoing strong antibiotics or steroid-type medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at cells from the lungs of people who developed lung inflammation after chest radiation for cancer. It aims to understand why some people get this reaction, which may help find better treatments.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Hear when a new Pneumonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.